Want to Participate in a Clinical Research Trial for Schizophrenia?
Fill out this quick Pre-Screening Questionnaire
About Schizophrenia
Schizophrenia
Schizophrenia is a mental disorder in which people interpret reality abnormally. Schizophrenia may result in some combination of hallucinations, delusions, and extremely disordered thinking and behavior that impairs daily functioning, and can be disabling.
Schizophrenia involves a range of problems with thinking (cognition), behavior and emotions. Signs and symptoms may vary, but usually involve delusions, hallucinations or disorganized speech, and reflect an impaired ability to function. Symptoms may include:
- Delusions. These are false beliefs that are not based in reality.
- Hallucinations. These usually involve seeing or hearing things that don’t exist.
- Disorganized thinking (speech). Disorganized thinking is inferred from disorganized speech.
- Extremely disorganized or abnormal motor behavior. This may show in a number of ways, from childlike silliness to unpredictable agitation. Behavior isn’t focused on a goal, so it’s hard to do tasks. Behavior can include resistance to instructions, inappropriate or bizarre posture, a complete lack of response, or useless and excessive movement.
- Negative symptoms. This refers to reduced or lack of ability to function normally.
Schizophrenia Clinical Research Studies
Schizophrenia Clinical Research Studies
Study A
Summary: The Journey study is evaluating the safety, efficacy, and tolerability of Valbenazine as Adjunctive or add on treatment in subjects with schizophrenia.
Eligibility Criteria
Key Inclusion Criteria:
- Experiencing cognitive impairment with a previous diagnosis of schizophrenia.
- Willing to comply with all study assessments and procedures.
- Currently taking an antipsychotic medication for at least 3 weeks prior to study entry at a 3-6mg Risperidone equivalent.
Key Exclusion Criteria:
- Diagnosed with bi-polar disorder or other non-schizophrenic psychotic disorders.
- Current substance/alcohol abuse.
- Clinically significant medical conditions.
Patient Time/Travel Reimbursed?
Yes
Age:
18 and older
___________________________________________________________________________________________________________________
Study B
Summary: The Recover study is evaluating the safety and efficacy of Brilaroxazine (RP5063) in subjects with acute exacerbation of schizophrenia.
Eligibility Criteria
Key Inclusion Criteria:
- Experiencing exacerbating symptoms of schizophrenia.
- Diagnosis of schizophrenia in in the past 1-20 years.
- Willing to comply with all study assessments and procedures.
- Currently taking an antipsychotic medication and willing to discontinue.
Key Exclusion Criteria:
- Diagnosed with bi-polar disorder or other non-schizophrenic psychotic disorders.
- History of taking Clozapine.
- Current substance/alcohol abuse.
- Clinically significant medical conditions.
Patient Time/Travel Reimbursed?
Yes
Age:
18-65
___________________________________________________________________________________________________________________
Study C
Summary: The Convoke study is evaluating the safety and efficacy of two digital therapeutics as an adjunctive or add on treatment to patients with negative symptoms of schizophrenia.
Eligibility Criteria
Key Inclusion Criteria:
- Experiencing exacerbating symptoms of schizophrenia.
- Current diagnosis of schizophrenia.
- Willing to comply with all study assessments and procedures.
- Currently taking an antipsychotic medication.
- Have a device with updated IOS or Android systems and an active email address.
Key Exclusion Criteria:
- Diagnosed with bi-polar disorder or other non-schizophrenic psychotic disorders.
- History of taking Clozapine.
- Current substance/alcohol abuse.
- Clinically significant medical conditions.
Patient Time/Travel Reimbursed?
Yes
Age:
18 and older
___________________________________________________________________________________________________________________
Study D
Summary: A placebo-controlled study evaluating the safety and efficacy of RL-007 in the treatment of cognitive impairment associated with schizophrenia.
Eligibility Criteria
Key Inclusion Criteria:
- Experiencing cognitive impairment associated with schizophrenia.
- Diagnosis of schizophrenia for at least 6 months.
- Willing to comply with all study assessments and procedures.
- Currently taking an antipsychotic medication for 4 weeks prior to study entry.
Key Exclusion Criteria:
- Diagnosed with bi-polar disorder or other non-schizophrenic psychotic disorders.
- History of taking Clozapine.
- Current substance/alcohol abuse.
- Clinically significant medical conditions.
Patient Time/Travel Reimbursed?
Yes
Age:
18-55
- Please complete this form to determine your eligibility for our Schizophrenia studies
Pre-screening questionnaire and your privacy
Please be advised that by filling out the study pre-screening questionnaire, you will be asked to provide personal information, including age, gender, and your current medical condition. One of our staff will then reach out to conduct a phone-screen to see if you qualify for one of our current studies at our office location in Oceanside, CA. Your privacy is of the utmost importance to Excell Research. Your privacy will be protected according to HIPAA regulations and the information you provide will only be shared with those involved with the clinical research study if it is determined that you may be eligible to participate, unless you permit us to do so or except as required by law. Your information will not be sold to outside companies, nor will it be stored or collected without your direct consent.
About clinical trials
Clinical research trials and those who contribute play a role in the development of new treatments for some of our most common and debilitating diseases and conditions.
Patients who participate in Excell’s research studies have an opportunity to join the vanguard of scientific research and contribute to the progress, knowledge, and future treatment of psychiatric or medical conditions.
We will provide you with comprehensive information and straightforward answers to your questions regarding the risks and benefits of participating.
Financial compensation may be available to those who qualify and complete visits for clinical trials at Excell.